Psyence Biomedical2025-05-21T12:37:34+02:00

Psyence Biomed

The world’s first life science biotechnology company traded on the Nasdaq (NASDAQ:PBM) focused on the development of botanical (nature derived, or non-synthetic) psilocybin-based psychedelic medicines. The name “Psyence” combines the words “psychedelics” and “science” to affirm Psyence Biomed’s commitment to an evidence-based approach to innovation as it works to develop safe and effective, nature-derived psychedelic therapeutics to treat a broad range of mental health disorders. Psyence Biomed is initially focused on mental health disorders in the context of Palliative Care.

Psyence Biomed

The  world’s first life science biotechnology company traded on the Nasdaq (NASDAQ:PBM) focused on the development of botanical (nature derived, or non-synthetic) psilocybin-based psychedelic medicines. The name “Psyence” combines the words “psychedelics” and “science” to affirm Psyence Biomed’s commitment to an evidence-based approach to innovation as it works to develop safe and effective, nature-derived psychedelic therapeutics to treat a broad range of mental health disorders. Psyence Biomed is initially focused on mental health disorders in the context of Palliative Care.

Informed by nature
and guided by science

Our 
Mission

To advance a portfolio of nature-derived, evidence-based therapeutics targeting unmet mental health needs in palliative care, addiction, and related conditions, through a fully integrated biotechnology platform with in-house capabilities in cultivation, manufacturing, and clinical development.

Pioneering the use of natural

psychedelics for mental health

We are a life science biotechnology company developing innovative, safe and effective psychedelic and nature-centred solutions for mental health.

Our key focus area is palliative care. In particular, Psyence is targeting the indications of anxiety and depression, and associated ailments, within the context of palliative care.

Leading the Business of Medicine and Science

Working at the intersection of medicine, commerce, and science, our physician-led company is headed by R+D leader CEO Dr. Neil Maresky, MD. Our expertise in intellectual property and capital markets and business development brings a global track record of sustainable growth and shareholder value.

Our News

We believe in keeping our stakeholders informed and engaged with clear and timely communication. Whether it’s news about our scientific breakthroughs, regulatory updates, or leadership commentary, this is your trusted source for all formal communications from Psyence Biomed.

Our Global Footprint

Psyence is listed on the NASDAQ Stock Exchange (NASDAQ: PBM)

Our Global Footprint

Psyence is listed on the NASDAQ Stock Exchange (NASDAQ: PBM)

Our News

  • Tony Budden - CEO PsyLabs

Insights Care Magazine – Tony Budden

May 19, 2025|

Discover the future of mental health care through the eyes of Tony Budden, CEO of PsyLabs, in his thought-provoking feature in Insights Care Magazine. As a pioneer in the development of nature-derived psychedelic compounds like psilocybin and ibogaine, PsyLabs—working in close partnership with Psyence Biomed—is advancing groundbreaking solutions for substance use disorders and other mental health challenges.

  • Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

April 21, 2025|

Psyence BioMed announced today that it received a notification letter dated April 16, 2025, from the Listings Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Rule”). The Staff's determination is based on the closing bid price of the Company’s common shares being below $1.00 for 30 consecutive business days from March 5, 2025 through April 15, 2025.

Go to Top